Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation
Moazzam Shahzad,Muhammad Kashif Amin,Polina Bellman,Joe Al‐Ramahi,Jawad Noor,Abhinav Vyas,Zahra Mahmoudjafari,Matthew McGuirk,Shaun DeJarnette,Nausheen Ahmed,Al‐Ola Abdallah,Leyla Shune,Anurag K. Singh,Joseph P. McGuirk,Sunil Abhyankar,Muhammad Umair Mushtaq
DOI: https://doi.org/10.1111/trf.17909
2024-06-09
Transfusion
Abstract:Background Nivestym, a biosimilar granulocyte colony‐stimulating factor (G‐CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We aim to compare the efficacy of Nivestym and Neupogen for PBSC mobilization in healthy allogeneic donors. Methods We conducted a retrospective single‐center study including 541 adult allo‐HSCT donors receiving Nivestym (January 2013–July 2020), or Neupogen (July 2020–June 2023) for donor PBSC mobilization. Bivariate analysis was conducted using SPSS version 28. Statistical significance was determined at a p‐value
hematology
What problem does this paper attempt to address?